Chronic olanzapine or sertindole treatment. Results in reduced oral chewing movements in rats compared to haloperidol

Neuropsychopharmacology

Volumn 19, Issue 5, 1998, Pages 428-433

  Gao, Xue Min ^a   Sakai, Kazuo ^a   Tamminga, Carol A ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

Chronic neuroleptic treatment; Dyskinesia; Haloperidol; Olanzapine; Sertindole; Tardive dyskinesia

Indexed keywords

HALOPERIDOL; OLANZAPINE; SERTINDOLE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DYSKINESIA; MALE; MASTICATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; TARDIVE DYSKINESIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DYSKINESIA, DRUG-INDUCED; HALOPERIDOL; IMIDAZOLES; INDOLES; MALE; MASTICATION; PIRENZEPINE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0032210966     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(98)00039-6     Document Type: Article

References (29)

1. Beasley C.M. Jr., Sanger T., Satterlee W., Tollefson G., Tran P., Hamilton S. Olanzapine versus placebo. Results of a double-blind, fixed-dose olanzapine trial Psychopharmacology. 124:1996;159-167.
2. Bianchetti G., Morselli P.I. Rapid and sensitive method for determination of haloperidol in human samples using nitrogen-phosphorous selection detection. J Chromatog. 153:1978;203-210.
3. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 14:1996;87-96.
4. Casey D.E. Behavioral effects of sertindole, risperidone, clozapine, and haloperidol in Cebus monkeys. Psychopharmacology. 124:1996;134-140.
5. Clow A., Theodorou A., Jenner P., Marsden C.D. Changes in cerebral dopamine function induced by a year's administration of trifluoperazine or thioridazine and their subsequent withdrawal. Adv Biochem Psychopharmacol. 24:1980;335-340.
6. Ellison G., See R., Levin E., Kinney J. Tremorous mouth movements in rats administered chronic neuroleptics. Psychopharmacology. 92:1987;122-126.
7. Fink-Jensen A., Kristensen P. Effects of typical and atypical neuroleptics on Fos protein expression in the rat forebrain. Neurosci Lett. 182:1994;115-118.
8. Gao X.-M., Kakigi T., Friedman M.B., Tamminga C.A. Tiagabine inhibits haloperidol-induced oral dyskinesias in rats. J Neu Transm. 95:1994;63-69.
9. Gao X.-M., Tamminga C.A. Phencyclidine produces changes in NMDA and kainate receptor binding in rat hippocampus over a 48 hour time course. Synapse. 23:1996;274-279.
10. Gao X.M., Hashimoto T., Cooper T.B., Tamminga C.A. The dose-response characteristics of rat oral dyskinesias with chronic haloperidol or clozapine administration. J Neural Transm. 104:1997;97-104.
11. Glenthoj B., Hemmingsen R. Intermittent neuroleptic treatment induces long-lasting abnormal mouthing in the rat. Eur J Pharmacol. 164:1989;393-396.
12. Grace A.A., Bunney B.S., Moore H., Todd C.L. Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs. Trends Neurosci. 20:1997;31-37.
13. Gunne L.M., Growdon J., Glaeser B. Oral dyskinesia in rats following brain lesions and neuroleptic drug administration. Psychopharmacology. 77:1982;134-139.
14. Hashimoto T., Ross D.E., Gao X.M., Tamminga C.A. Mixture in the distribution of haloperidol-induced oral dyskinesias in the rat supports an animal model of tardive dyskinesia. Psychopharmacology. 137:1998;107-112.
15. Kakigi T., Gao X.M., Tamminga C.A. Drug-induced oral dyskinesias in rats after traditional and new neuroleptics. J Neural Transm. 101:1995;41-49.
16. Kane JM, Woerner M, Borenstein M, Wegner J, Liberman J (1986): Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 254-258.
17. McKinney W.T., Bunney W.E. Animal models of depression. Arch Gen Psychiat. 21:1969;240-248.
18. Robertson G.S., Fibiger H.C. Effects of olanzapine on regional c-fos expression in rat forebrain. Neuropsychopharmacology. 14:1996;105-110.
19. Robertson G.S., Matsumura H., Fibiger H.C. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Therapeu. 271:1994;1058-1066.
20. Sanchez C., Arnt J., Dragsted N., Hyttel J., Lembol H.L., Meier E. Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Devel Res. 22:1991;239-250.
21. 1 binding site correlates of haloperidol-induced oral dyskinesias in rat. Implications for the mechanism of tardive dyskinesia Exper Neurol. 127:1994;62-69.
22. Skarsfeldt T. Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurons in rats. Acute and repeated treatment Synapse. 10:1992;25-33.
23. Skarsfeldt T. Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat. Eur J Pharmacol. 281:1995;289-294.
24. Tamminga C.A., Dale J.M., Goodman L., Kaneda H., Kaneda N. Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia. A study in three rat strains Psychopharmacology. 102:1990;474-478.
25. Tollefson G.D., Beasley C.M. Jr., Tamura R.N., Tran P.V., Potvin J.H. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiat. 154:1997;1248-1254.
26. VanPutten T., Marder S.R., Wirshing W.C., Aravagiri M., Chabert N. Neuroleptic plasma levels. Schizophr Bull. 17:1991;197-216.
27. Waddington J.L. Spontaneous orofacial movements induced in rodents by very long-term neuroleptic drug administration. Phenomenology, pathophysiology, and putative relationship to tardive dyskinesia Psychopharmacology. 101:1990;431-447.
28. Weiss J.M., Kilts C.D. Animal models of depression and schizophrenia. Schatzberg A.F., Nemeroff C.V. Textbook of Psychopharmacology. 1995;81-123 American Psychiatric Press, Washington, DC.
29. Zimbroff D.L., Kane J.M., Tamminga C.A., Daniel D.G., Mack R.J., Wozniak P.J., Sebree T.B., Wallin B.A., Kashkin K.B., The Sertindole Study Group A controlled, dose-response study of sertindole and haloperidol in schizophrenia. Am J Psychiat. 154:1997;782-791.